Alk-Abello ASCHIX:ALKBC 93 3-Year ROIIC % is 50.30 as of Dec. 2025, which is 78% above its 10-year median of 28.29. GuruFocus rates CHIX:ALKBC with a GF Score™ of 93/100 and a GF Value™ of kr207.61 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,319 Biotechnology companies, Alk-Abello AS ranks better than 71.65% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Alk-Abello AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 50.30%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Alk-Abello AS's 3-Year ROIIC % or its related term are showing as below:
CHIX:ALKBc's 3-Year ROIIC % is ranked better than 71.65% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs CHIX:ALKBc: 50.30
Alk-Abello AS (CHIX:ALKBc) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Alk-Abello AS 3-Year ROIIC % Related Terms
Alk-Abello AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Alk-Abello AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's 3-Year ROIIC % falls into.
Alk-Abello AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 1210.8934 (Dec. 2025) - 352.218 (Dec. 2022) )
/
( 6939 (Dec. 2025) - 5232 (Dec. 2022) )
=
858.6754
/
1707
=
50.30%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Alk-Abello AS (CHIX:ALKBC) has a 3-Year ROIIC % of 50.30 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Alk-Abello AS and its competitors. This is 78% above median its historical median of 28.29. According to the industry distribution chart, Alk-Abello AS ranks #374 out of 1319 companies in the Biotechnology industry, placing it in the top 28.4%.
Is Alk-Abello AS's 3-Year ROIIC % too high?
Alk-Abello AS's current 3-Year ROIIC % of 50.30 is 78% above median its 10-year median of 28.29. Based on the distribution chart, Alk-Abello AS ranks #374 out of 1319 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #374 out of 1319 companies for 3-Year ROIIC %. This puts Alk-Abello AS in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Alk-Abello AS and its competitors. Alk-Abello AS's current 3-Year ROIIC % is 50.30, which is 78% above median its own 10-year median of 28.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.61, compared to a current price of kr256.30 — trading 23.5% above its estimated fair value. The current 3-Year ROIIC % is 50.30, which is 78% above median its 10-year median of 28.29. Alk-Abello AS's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current 3-Year ROIIC % is 50.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 23.5% above its estimated GF Value™ of kr207.61.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
3-Year ROIIC %: 50.30 (78% above median its 10-year median of 28.29)
GF Value™: kr207.61 vs. price of kr256.30 (23.5% above fair value)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
93GF Score
Get the complete analysis for CHIX:ALKBC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
